Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Steven A. Blahut"'
Publikováno v:
Health Services Research. 40:2140-2161
Objective To describe translation and cultural adaptation procedures, and examine the degree of equivalence between the Spanish and English versions of the Agency for Healthcare Research and Quality's (AHRQ) Consumer Assessments of Healthcare Provide
Autor:
Stephen T. Bartlett, Steven A. Blahut, Jeffrey C. Fink, Matthew R. Weir, Benjamin Philosophe, Beth Copenhaver, A Wiland, M. Ryan Weir
Publikováno v:
Transplantation. 77:422-425
Background. Living-donor kidney transplant recipients generally do not receive antibody induction. Induction avoidance may not be appropriate, particularly for living-unrelated renal transplant (LURT) recipients, in whom matching may not be optimal.
Autor:
David K. Klassen, Cinthia Drachenburg, Steven A. Blahut, Stephen T. Bartlett, John Papademitriou, Matthew R. Weir, Charles B. Cangro, Jeffrey C. Fink, Cindi Young
Publikováno v:
American Journal of Nephrology. 24:379-386
Chronic allograft nephropathy is a major cause of progressive renal failure in renal transplant recipients. Its etiology is multifactorial and may include both immunologic and nonimmunologic causes. In this observational cohort study we set out to se
Publikováno v:
Journal of the American Society of Nephrology. 13:2338-2344
End-stage renal disease (ESRD) patients treated with hemodialysis have a high mortality rate, which is largely due to inadequate dialysis. Dialysis adequacy, measured by the urea reduction ratio (URR), tends to be correlated within dialysis facilitie
Publikováno v:
American Journal of Kidney Diseases. 37:348-355
Erythropoietin (EPO) is recommended in individuals progressing toward end-stage renal disease (ESRD) to correct anemia and its complications, which are common in this disease. This study evaluated the impact of EPO administered before dialysis on mor
Autor:
Matthew R. Weir, Robert Sawyer, William L. Henrich, Muhammad Salmanullah, Michael K. Hise, Jeffrey C. Fink, Steven A. Blahut
Publikováno v:
American Journal of Nephrology. 21:386-389
Although it is anticipated that most patients with renal insufficiency will progress towards end-stage renal disease (ESRD) there have been few population-based studies to validate this assumption. We examined serial creatinines from 3,874 anonymous
Publikováno v:
Journal of the American Society of Nephrology. 12:164-169
Efforts to improve the delivery of hemodialysis have focused mostly on identifying patient-related factors that lead to inadequate dialysis. Less consideration has been given to the impact of the dialysis center on adequacy. This study evaluated whet
Autor:
Lisa M. Shickle, Paul D. Light, Steven A. Blahut, Jeffrey C. Fink, Stacy J. Kurth, Mary S. Turner, Rachel A. Burdick, Nancy Armistead
Publikováno v:
American Journal of Kidney Diseases. 34:694-701
The appropriate use of serum creatinine level as a surrogate for time in the course of renal failure when dialysis commences requires it to be a significant predictor of mortality in incident patients with end-stage renal disease (ESRD). This study e
Autor:
Cinthia B. Drachenberg, Charles B. Cangro, Steven A. Blahut, Matthew R. Weir, Stephen T. Bartlett, Ann Wiland, David K. Klassen, Jeffrey C. Fink, John C. Papadimitriou
Publikováno v:
Transplantation. 68:396-402
Background The introduction of the potent immunosuppressive drugs tacrolimus (FK) and cyclosporine (CSA) has markedly improved the outcome of solid organ transplantation. However, these drugs can cause posttransplantation diabetes mellitus. Abnormali
Autor:
Matthew Cooper, Ravinder K. Wali, M. Dinits, Charles B. Cangro, Clarence E. Foster, Benjamin Philosophe, J Nogueira, J. C. Papadimitriou, Matthew R. Weir, Steven A. Blahut, Viresh Mohanlal, S. T. Bartlett, Cinthia B. Drachenberg, Ashish Joshi, Emilio Ramos
Publikováno v:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 7(6)
Mammalian Target-of-Rapamycin inhibitors (mTOR inhibitors) can be used to replace the calcineurin inhibitors (CNIs) to prevent progression in chronic kidney disease (CKD) following organ transplantation. Discontinuation of tacrolimus in 136 recipient